Curaleaf Holdings, Inc. Earnings Recaps
Q1 2026
May 7, 2026
Shares jumped 16.4% as Curaleaf delivered revenue growth that outpaced guidance and internal expectations, driven by strength in its international segment and supportive regulatory developments.
Key takeaways
- Q1 revenue rose 6% year-over-year to $324 million, beating guidance and internal forecasts.
- International segment revenue surged 35%, highlighting the growing importance of Curaleaf’s global platform.
- Gross margin stood at 49%, with adjusted EBITDA of $63 million representing a 20% margin, despite a 170 basis point margin drag from international investments.
- Net income from continuing operations was $70 million ($0.09 per share), a significant turnaround from last year’s loss of $50 million.
- Regulatory progress, including medical cannabis rescheduling and potential 280E tax relief, underpinned investor enthusiasm and improved liquidity with a $500 million refinancing facility.
Q3 2025
Nov 6, 2025
Curaleaf Holdings reported a modest revenue increase to $320 million in Q3 2025, driven by stable domestic performance and strong international growth, while achieving enhanced margins and maintaining a healthy cash position.
Key takeaways
- Revenue grew 2% sequentially, with international segment up 12% sequentially and 56% year-over-year.
- Adjusted gross margins improved to 50%, reflecting a 115 basis point increase.
- Achieved $69 million in adjusted EBITDA, with a 22% margin despite headwinds from international operations.
- Strong cultivation improvements led to average flower potency exceeding 30% for the first time.
- Closed a $100 million revolving credit line to improve financial flexibility and reduce debt obligations.